<!DOCTYPE html>
<html>
<head>
    <title>BREAKING: Federal Register: Clinical Immunogenicity Considerations for Biosimilar and Interchangeable Insulin Products; Draft Guidance for Industry; Availability</title>
    <meta charset="UTF-8">
    <style>
        body { font-family: Georgia, serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { border-bottom: 2px solid #333; }
        .breaking { background: #fff3cd; border-left: 4px solid #dc3545; padding: 15px; }
        .source { background: #f8f9fa; padding: 10px; margin-top: 20px; font-size: 0.9em; }
        .timestamp { color: #666; }
    </style>
</head>
<body>
    <h1>BREAKING: Federal Register: Clinical Immunogenicity Considerations for Biosimilar and Interchangeable Insulin Products; Draft Guidance for Industry; Availability</h1>
    <p class="timestamp">Published: 2019-11-29 | Source: Federal Register</p>
    <div class="breaking">
        <p><strong>The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Clinical Immunogenicity Considerations for Biosimilar and Interchangeable Insulin Products." The purpose of this draft guidance is to provide recommendations to applicants regarding whether and when comparative clinical immunogenicity studies may be needed to support licensure of proposed biosimilar and interchangeable recombinant human insulins, recombinant human insulin mi...</strong></p>
    </div>
    <h2>Document Details</h2>
    <p><strong>Document Type:</strong> Notice</p>
    <p><strong>Agency:</strong> Health and Human Services Department, Food and Drug Administration</p>
    <p><strong>Document Number:</strong> 2019-25919</p>
    <p><strong>Publication Date:</strong> 2019-11-29</p>
    <h2>Official Source</h2>
    <p>Read the full document at: <a href="https://www.federalregister.gov/documents/2019/11/29/2019-25919/clinical-immunogenicity-considerations-for-biosimilar-and-interchangeable-insulin-products-draft">https://www.federalregister.gov/documents/2019/11/29/2019-25919/clinical-immunogenicity-considerations-for-biosimilar-and-interchangeable-insulin-products-draft</a></p>
    <div class="source"><strong>Source:</strong> Federal Register - 2019-25919</div>
    <p><a href="index.html">Back to Breaking News Wire</a></p>
</body>
</html>
